Bioharvest sciences reports fourth quarter and full year 2024 financial results

Fourth quarter revenues grew 62% to $7.3 million, exceeding prior management guidance, with full year revenues increasing 99% year-over-year to $25.2 million cdmo division secures anchor partnership with tate & lyle to develop next generation of plant-based sweeteners rehovot, israel--(newsfile corp. - march 31, 2025) - bioharvest sciences inc. (nasdaq: bhst) (fse: 8mv0) ("bioharvest" or the "company"), a company pioneering its patented botanical synthesis technology platform, today reported its financial and operational results for the fourth quarter and full year ended december 31, 2024. fourth quarter 2024 & subsequent operational highlights all figures stated in this news release are in u.s. dollars unless stated otherwise.
BHST Ratings Summary
BHST Quant Ranking